Clinical trials for acute leukemia targeting older or chemotherapy-ineligible patients are enrolling a surprisingly high number of younger individuals. This trend blurs the lines of the intended patient population and affects how trial data should be interpreted and generalized to real-world practice.
The adverse reaction to menin inhibitors is not limited to typical differentiation syndrome (DS) pulmonary symptoms. It presents as a broad 'menin syndrome' with diverse manifestations like bone pain, rashes, and swollen lymph nodes, requiring a new diagnostic framework for clinicians.
Differentiation syndrome with menin inhibitors is more frequent and intense than with IDH inhibitors, meaning clinicians cannot be complacent. It requires an emergency-level response: immediate hospital admission, steroids, holding the drug, and a low threshold to escalate treatment with cytarabine if needed.
When patients on menin inhibitors show worsening symptoms in early weeks, it's hard to distinguish disease progression from differentiation syndrome. The recommended clinical strategy is to default to treating for differentiation syndrome first, as it may be a manageable side effect rather than treatment failure.
The development of regimens like SAVE (oral decitabine, venetoclax, revumenib) demonstrates that complex, effective combination therapies for acute leukemia can be administered entirely orally. This marks a paradigm shift towards more convenient, less burdensome treatment that reduces time in the hospital or clinic.